Our Business

Russia, Ukraine and CIS

Russia, Ukraine and CIS in numbers

  • €45mSales 2016
  • +25%Annual growth 2016
  • >620Number of employees
  • Sales 2016
  • Annual growth 2016
  • Number of employees


  • CNS market leader with 30% market share in Ukraine

  • 8th largest pharmaceutical production company in Ukraine

Acino’s business across the CIS region currently covers Ukraine, Russia, Kazakhstan, Belarus, Uzbekistan, Turkmenistan and Georgia, with a remarkable 25% sales growth for 2016 compared to 2015. Acino established its footprint in the region with the acquisition of Copharm in Russia in December 2014 and of Pharma Start in Ukraine in October 2015.

Acino Pharma Start develops, manufactures and commercializes a unique and patented portfolio of advanced generic drugs in the therapeutic areas of Cardiovascular, Central Nervous System (CNS), Women Health and Over-The-Counter products (OTC).

The site in Kiev is our regional headquarter and home to the commercial organization of Ukraine and the GMP-certified manufacturing plant.

Acino’s entity in Russia is a fast-growing pharmaceutical company with an exclusive portfolio of original products for diverse therapeutic areas focusing on female healthcare and cardiology. The business in Russia is managed via our regional office in Moscow.

Our commercial success in the region is built on a close and strong cooperation with key business partners, healthcare professionals and patients. We are committed to delivering health solutions to patients with high quality and maximum safety as well as educational activities for the healthcare community.


  • Addresses

    Acino Pharma Start

    blvd. I. Lepse, 8
    03124 Kyiv

  • Contact

    Eugene Zaika

    Regional Head Ukraine and CIS
    Phone +38 044 281 23 33

  • Acino Rus LLC

    10 Palikha str bld 3
    Office B-3

  • Contact

    Natalia Polushkina

    General Manager Russia
    Phone +7 495 502 92 47